The presence of the sodium–iodide symporter (NIS) at the plasma membrane (PM) of differentiated thyroid cancer (DTC) cells is required for the successful use of radioiodine (RAI) therapy in these malignancies. Here, SLC5A5 is linked to thyroid gland carcinoma.